DK0973806T3 - Sted-beskyttet proteinmodificering - Google Patents

Sted-beskyttet proteinmodificering

Info

Publication number
DK0973806T3
DK0973806T3 DK98911482T DK98911482T DK0973806T3 DK 0973806 T3 DK0973806 T3 DK 0973806T3 DK 98911482 T DK98911482 T DK 98911482T DK 98911482 T DK98911482 T DK 98911482T DK 0973806 T3 DK0973806 T3 DK 0973806T3
Authority
DK
Denmark
Prior art keywords
protein
polyethylene glycol
site
activity
conjugating
Prior art date
Application number
DK98911482T
Other languages
English (en)
Inventor
Dean K Pettit
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0973806T3 publication Critical patent/DK0973806T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98911482T 1997-03-10 1998-03-05 Sted-beskyttet proteinmodificering DK0973806T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/814,305 US6548644B1 (en) 1997-03-10 1997-03-10 Site protected protein modification
EP98911482A EP0973806B1 (en) 1997-03-10 1998-03-05 Site protected protein modification
PCT/US1998/004301 WO1998040409A1 (en) 1997-03-10 1998-03-05 Site protected protein modification

Publications (1)

Publication Number Publication Date
DK0973806T3 true DK0973806T3 (da) 2005-01-31

Family

ID=25214667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911482T DK0973806T3 (da) 1997-03-10 1998-03-05 Sted-beskyttet proteinmodificering

Country Status (10)

Country Link
US (1) US6548644B1 (da)
EP (1) EP0973806B1 (da)
JP (1) JP3708134B2 (da)
AT (1) ATE277084T1 (da)
AU (1) AU6542598A (da)
DE (1) DE69826452T2 (da)
DK (1) DK0973806T3 (da)
ES (1) ES2229485T3 (da)
PT (1) PT973806E (da)
WO (1) WO1998040409A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
MXPA04008149A (es) * 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
DE102004005710A1 (de) * 2004-02-05 2006-05-04 Siemens Ag Biosensor und Verfahren zu dessen Betrieb
DE102004005711A1 (de) * 2004-02-05 2006-05-11 Siemens Ag Biosensor zur Bestimmung eines Allergenes mit Betriebsverfahren
AU2005275108B2 (en) * 2004-07-16 2011-05-12 Nektar Therapeutics Conjugates of a GM-CSF moiety and a polymer
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2285350B1 (en) * 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
PL2349341T3 (pl) * 2008-10-15 2014-03-31 Baxalta Inc Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2507267B1 (en) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
AU2011212929B2 (en) 2010-02-04 2016-10-27 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
AU2012228990B2 (en) 2011-03-16 2017-04-06 Amgen Inc. Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1.7之強效及選擇性抑制劑
MX370689B (es) 2014-06-10 2019-12-19 Amgen Inc Polipeptidos apelina.
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
US20230102464A1 (en) * 2020-01-15 2023-03-30 Jenkem Technology Co., Ltd. (Tianjin) Method for preparing pegylated biomolecule with controllable binding sites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5235028A (en) * 1990-08-31 1993-08-10 University Of Minnesota Polyethylene glycol derivatives for solid-phase applications
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IT1260468B (it) * 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
AU3830895A (en) * 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors

Also Published As

Publication number Publication date
JP2001506670A (ja) 2001-05-22
DE69826452T2 (de) 2006-02-16
EP0973806B1 (en) 2004-09-22
JP3708134B2 (ja) 2005-10-19
DE69826452D1 (de) 2004-10-28
AU6542598A (en) 1998-09-29
EP0973806A1 (en) 2000-01-26
US6548644B1 (en) 2003-04-15
WO1998040409A1 (en) 1998-09-17
ES2229485T3 (es) 2005-04-16
ATE277084T1 (de) 2004-10-15
PT973806E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
DK0973806T3 (da) Sted-beskyttet proteinmodificering
WO1999067291A3 (en) Site specific protein modification by mutagenesis
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
AU9174398A (en) Peptides
DK1200479T3 (da) Multiple cytokin-antistof-komplekser
EP1023080A4 (en) LEAGUE BINDING POINT OF RAGE AND THEIR USE
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
TR200102703T2 (tr) Katı nesnelerin hat üzerinde üretimi.
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DK1055685T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE513056T1 (de) Stabilisierte proteine
DK0904062T3 (da) Ionkonjugat med depotvirkning
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
TR199802394A3 (tr) Proteinleri stabilize etmek için gelistirilmis proses.
DE69731463D1 (de) Rekombinante ribonuklease proteine
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
DE69619257D1 (de) Die konjugation von liganden an immobilisierte proteine in einem organischen lösungsmittel
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
EP1023906A4 (en) POTENTIATOR FOR ANTI-TUMOR ANTIBODY LYMPHOID
EP1200476A4 (en) ANTITUMAN ANTIBODIES, PROTEINS AND ITS USE
NL1010527A1 (nl) Pelletizeren van erts.
DE68911599D1 (de) GTP bindendes Protein und Verfahren zu dessen Herstellung.
ES1027614U (es) Inyector de cola perfeccionado.